Business Wire

CARBIOS

8.2.2023 06:51:15 CET | Business Wire | Press release

Share
Carbios appoints four new Board members to strengthen international expertise in brand development, business growth and scientific research

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005964/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Clockwise from left: Mateus SCHREINER GARCEZ LOPES, Sandrine CONSEILLER, Prof. Karine AUCLAIR & Amandine DE SOUZA

Carbios (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies for reinventing the life cycle of plastics and textiles, announces the appointment of four new members to its Board of Directors.

Prof. Karine AUCLAIR, professor of Chemistry at McGill University, Sandrine CONSEILLER, former CEO of Aigle, Amandine DE SOUZA, General Manager of LE BHV MARAIS, Eataly and Home, DIY and Leisure Purchasing at Galeries Lafayette Group, and Mateus SCHREINER GARCEZ LOPES, Global Director for Energy Transition and Investments at Raizen, have all been appointed members of Carbios’ Board of Directors. Three of the new members have strong, proven expertise in various industries covering fashion, retail and energy, as well as business development and senior executive management in high-growth markets and sectors around the world. The new scientific expertise will also help enhance and advance Carbios’ research into biological solutions for the life cycle of plastics and textiles. In addition, a sensitivity to CSR issues and proven results in this field was also a key selection factor to join the Board. The new members’ combined strategic vision, solid industry experience and CSR commitments will support Carbios in its industrial and commercial plans.

In the new structure, Prof. Karine AUCLAIR succeeds Jacqueline LECOURTIER, Sandrine CONSEILLER succeeds Jean FALGOUX, Amandine DE SOUZA succeeds Alain CHEVALLIER, and Mateus SCHREINER GARCEZ LOPES succeeds Jean-Claude LUMARET.

“We wish to thank Jacqueline Lecourtier, Jean Falgoux, Alain Chevallier and Jean-Claude Lumaret for their strong contribution to Carbios over the years, helping the company to grow from the early R&D phase to pre-commercial stage. As Carbios now moves towards its industrial and commercial stage, and prepares internationalization, bringing new expertise to the Board is key to success,” commented Philippe POULETTY, Chairman of Carbios’ Board of Directors. “Furthermore the election of three new female board members, Prof. Karine Auclair, Sandrine Conseiller and Amandine De Souza, along with Mateus Schreiner Garcez Lopes, all with stellar professional and complementary backgrounds, and who share our passion to help clean the planet with radical innovation, is a strong signal of Carbios’ commitment to ESG criteria.”

APPOINTMENTS TO THE BOARD OF DIRECTORS

Prof. Karine AUCLAIR is Professor of Chemistry at McGill University and holds the Tier 1 Canada Research Chair in Antimicrobials and Green Enzymes. She has received numerous awards over the years, including the Clara Benson Award of the Canadian Society of Chemistry, the McGill Tomlinson Professorship, the Leo Yaffe Teaching Award, and the McGill Fessenden Professorship, to name a few. She is an internationally recognized bioorganic chemist with significant scientific contributions to the fields of antimicrobial resistance, biocatalysis and enzymology. Her research led to several patents notably in the clean enzymatic depolymerization of untreated, high crystallinity PET plastics for closed-loop recycling. Her work has been published in nearly 100 peer-reviewed publications in high-impact journals, and often highlighted by the media. As a recognized leader in her field, she is often invited to speak at industrial and academic conferences around the world, and to review theses and grant applications for worldwide institutions.

Prof. Karine AUCLAIR: “From my expertise with enzymes in moist-solid mixtures, I am excited to join the Board of Carbios and contribute to the development and growth of plastic biorecycling and biodegradation.”

Sandrine CONSEILLER is former Chief Executive Officer of Aigle (the emblematic French brand committed to sustainable fashion). Prior to joining Aigle, Sandrine was Group Marketing & Branding Executive Vice-President at Lacoste (another historic French fashion brand) from 2011 to 2015. She contributed to the Lacoste maison turnaround with strong growth and numerous professional awards including several Cannes Lions Awards. She was also Member of the Executive Board. Sandrine began her career at Unilever and spent 20 years leading global businesses within various divisions, mainly in Personal Care, in Latin America, Europe, and Asia. Sandrine is also Member of the Board of Phildar (the iconic French knitwear brand), Member of the Board of Raise Sherpa (the first philantropic endowment fund dedicated to start-ups) and is a funding partner of NEO FOUNDERS (a venture fund mentoring impact start-ups).

Sandrine CONSEILLER: “I feel privileged and humbled to join Carbios’ Board of Directors and take part in a transformative adventure that will impact both the fashion and beauty industries, as well as the world we will leave for our children.”

Amandine DE SOUZA is General Manager of LE BHV MARAIS (French retail, decoration and fashion department stores), Eataly (an Italian gastronomy concept franchise) and Home, DIY and Leisure Purchasing at Galeries Lafayette Group since 2018. She has been a Member of its Executive Committee since 2020. Amandine has 17 years' experience in different types of companies of various sizes: from family business, to start-up, and multinational. She was General Manager for France at Westwing (an e-commerce start-up) from 2015 to 2018. From 2009 to 2015, she was International Merchandise Director at Casino Group (food and non-food retail distribution). Prior to this, she worked as a strategic consultant at Bain & Company within their Distribution and Consumer Goods Division in France and internationally.

Amandine DE SOUZA: “I am delighted to join the Board of Carbios, an extremely innovative company tackling the major issue of plastic pollution. I will be working alongside the company to support its international development and find the best ways to enhance its performance.”

Mateus SCHREINER GARCEZ LOPES is Global Director for Energy Transition and Investments at Raizen (global leader in bioenergy from Brazil), leading technology, new business development and intellectual property at the company. He was previously Global Manager for Innovation and Business Development in Renewable Chemicals at Braskem (the largest producer of thermoplastic resins in the Americas and the world’s largest producer of biopolymers). Before his transition to the corporate world, Mateus held several researcher and lecturer positions on Synthetic Biology and metabolic Engineering at Universities in Mexico, Germany, United States and Brazil. He is also a Board Member of Iogen Energy Corporation, Vice-Chairman of the Board of the Brazilian Association of Bio Innovation, and Advisory Committee Member from the MIT Energy Initiative.

Mateus SCHREINER GARCEZ LOPES: “I am thrilled to be involved in Carbios’ mission of reshaping the plastics and textile industries with circular processes. Carbios has a world-class team of scientists and entrepreneurs, and by joining the Board, my expertise in bringing new renewable technologies to market will help to design its R&D and commercialization strategy.”

Members of Carbios’ Board of Directors:

  • Dr. Philippe POULETTY, Chairman
  • Prof. Karine AUCLAIR
  • Sandrine CONSEILLER
  • Prof. Juan DE PABLO
  • Amandine DE SOUZA
  • Vincent KAMEL
  • Emmanuel LADENT
  • Isabelle PARIZE
  • Laurent SCHMITT, representative for BOLD (Business Opportunities for l’Oréal Development)
  • Mateus SCHREINER GARCEZ LOPES
  • Nicolas SEEBOTH, representative for Michelin Ventures
  • Alen VUKIC, censor

Visit the Carbios website for individuel Board Member biographies: https://www.carbios.com/en/governance/

About Carbios

Established in 2011 by Truffle Capital, Carbios is a green biotech company, developing biological and innovative processes. Through its unique approach of combining enzymes and plastics, Carbios aims to address new consumer expectations and the challenges of a broad ecological transition by taking up a major challenge of our time: plastic and textile pollution. Carbios deconstructs any type of PET (the dominant polymer in bottles, trays, textiles made of polyester) into its basic components which can then be reused to produce new PET plastics with equivalent quality to virgin ones. This PET innovation, the first of its kind in the world, was recently recognized in a scientific paper published in front cover of the prestigious journal Nature. Carbios successfully started up its demonstration plant in Clermont-Ferrand in 2021. It has now taken another key step towards the industrialization of its process with the construction of a first-of-a-kind unit in partnership with Indorama Ventures.

In 2017, Carbios and L’Oréal co-founded a consortium to contribute to the industrialization of its proprietary recycling technology. Committed to developing innovative solutions for sustainable development, Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe joined this consortium in April 2019. In 2022, Carbios signed an agreement with On, Patagonia, PUMA, and Salomon, to develop solutions promoting the recyclability and circularity of their products.

The Company has also developed an enzymatic biodegradation technology for PLA-based (a bio sourced polymer) single-use plastics. This technology can create a new generation of plastics that are 100% compostable at ambient temperatures, even in domestic conditions, integrating enzymes at the heart of the plastic product.

For more information, please visit www.carbios.com/en / Twitter: Carbios LinkedIn: Carbios Instagram: insidecarbios

Carbios (ISIN FR0011648716/ALCRB) is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.

Translation is for information purposes only.
In case of discrepancy between the French and the English version of this press release, the English version shall prevail

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005964/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Askey and Canoga Perkins Announce Strategic Collaboration at MWC Barcelona to Deliver Rapid-Deploy 5G Critical Communications Solutions27.3.2026 12:00:00 CET | Press release

Askeyand Canoga Perkinsannounced at Mobile World Congress Barcelona a Global Partnership to Deliver SyncMetra® Network Connectivity Solution, combining Canoga Perkins’ software-defined, IT-operated private 5G network transport along with Askey’s carrier-grade 5G radio access technology. At MWC Barcelona 2026, Askey Computer Corporation and Canoga Perkins announced a strategic partnership to deploy Canoga Perkins' SyncMetra® Platform across enterprise and service provider markets with Askey. This partnership pairs Askey’s carrier-grade radio access capabilities with Canoga Perkins’ industry-leading time-sensitive networking (TSN) and synchronization technology, enabling customers to simplify deployment of ultra-low-latency, highly reliable network services for 5G, edge compute, industrial automation, and mission-critical enterprise applications. The partnership enables joint go-to-market efforts, integrated product offerings, and expanded access to SyncMetra through Askey’s sales channe

SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results27.3.2026 11:40:00 CET | Press release

Q4 EPS more than doubles to $0.14 as profitability improves significantly year over year SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial results for the fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025). Fourth Quarter 2025 Highlights Total revenues were $40 million, representing an 11% year-over-year decrease. Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.14 for the three months ended December 31, 2025, representing 133% year-over-year increase. EBITDA1, which is calculated by adding depreciation and amo

NIQ Redefines Packaging Intelligence with Monthly, Harmonized Global Performance Visibility27.3.2026 11:00:00 CET | Press release

NIQ’s new solution brings unprecedented clarity into package types, materials, and true consumption across markets, closing critical industry gaps NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of its Packaging Strategic Planner Global (SPG) Solution, the first harmonized global platform to deliver monthly visibility into packaging performance across materials, formats, and pack configurations. As packaging innovation accelerates, many organizations continue to rely on fragmented or annual data to inform packaging decisions. The Packaging SPG Solution closes this gap by providing real-time data delivered monthly across regions, enabling brands and packaging partners to uncover trends, grow revenue, and strengthen relationships with CPG and retail partners. Key Highlights: New monthly global packaging tracking capability Coverage across 200+ categories Visibility into 30+ package types and 20 package materials 10+ markets at launch, expanding

European DataWarehouse Claims Its First “Fintech Provider of the Year” Award and a Sixth “Data Provider of the Year” Title at GlobalCapital’s 2026 European Securitisation Awards27.3.2026 08:47:00 CET | Press release

European DataWarehouse (EDW) is pleased to announce that it has been named both “Data Provider of the Year” and “Fintech Provider of the Year” at the 2026 GlobalCapital European Securitization Awards in London. The award ceremony recognises outstanding achievements in European structured finance, with winners selected by popular vote from across the industry. As defined by GlobalCapital, the programme celebrates “the very best in the market, as chosen by the market.” This latest recognition marks the sixth time that EDW has received the prestigious Data Provider of the Year award, having previously been honoured in 2019, 2022, 2023, 2024 and 2025, reaffirming its long-standing commitment to transparency, data quality and innovation in European securitisation. Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “ Winning this award for the sixth time highlights the continued trust the European securitisation market places in EDW. Transparency, data quality and reliabili

Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye